Valneva SE (VALN)

In a March 23 joint press release, Pfizer said it’s confident in the vaccine’s potential and is planning regulatory submissions for approval. Citing Pfizer’s communication, Lingelbach said a filing is planned for the second half of 2026.
https://www.fiercebiotech.com/biotech/valneva-ceo-pfizer-partnered-lyme-vaccine-why-phase-3-miss-doesnt-tell-whole-story
“What I’ve learned in my 30-plus years,” Lingelbach said, “it’s not a good idea to shape a company for being bought. It is a good idea to do your job properly, and if someone comes and buys you that creates value, […] we’re gonna deal with it. That’s our job. But we are not shaping the company or building a strategy for exit.”

Valneva to Participate in Multiple Events at the 26th World Vaccine Congress in Washington DC
Lyon (France), March 26, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced its participation in the upcoming 26th World Vaccine Congress, which will take place from March 31 to April 2, 2026 at the Walter E. convention center in Washington, D.C. Led by the Company´s Chief Executive Officer, Thomas Lingelbach, a team of Valneva´s senior executives will participate in multiple events throughout the conference.
https://valneva.com/press-release/valneva-to-participate-in-multiple-events-at-the-26th-world-vaccine-congress-in-washington-dc/

March 18, 2026
Total revenues of €174.7 million in line with guidance, including €157.9 million in product sales
Strong year-end cash position of €109.7 million, with enhanced financial flexibility following successful debt refinancing and a 21% reduction in operating cash burn
2026 to be a potentially transformational year with Phase 3 Lyme disease data expected in the first half of the year

Valneva and Instituto Butantan Announce Initiation of a Pilot Vaccination Campaign in Brazil with Single-Shot Chikungunya Vaccine IXCHIQ®
Brazil's population is approximately 213.3 to 213.4 million

https://valneva.com/press-release/valneva-and-instituto-butantan-announce-initiation-of-a-pilot-vaccination-campaign-in-brazil-with-single-shot-chikungunya-vaccine-ixchiq/

George Maybach
2026-01-14 12:44
US :VALN
US

The average one-year price target for Valneva SE - Depositary Receipt (NasdaqGS:VALN) has been revised to $16.85 / share. This is an increase of 10.89% from the prior estimate of $15.20 dated December 20, 2025.

The price target is an average of many targets provided by analysts. The latest targets range from a low of $7.60 to a high of $24.31 / share. The average price target represents an increase of 67.91% from the latest reported closing price of $10.04 / share.
There are 20 funds or institutions reporting positions in Valneva SE - Depositary Receipt.

Novo Holdings A holds 2,345K shares. In its prior filing, the firm reported owning 2,375K shares , representing a decrease of 1.28%. The firm increased its portfolio allocation in VALN by 93.96% over the last quarter.

Frazier Life Sciences Management holds 2,292K shares. In its prior filing, the firm reported owning 1,458K shares , representing an increase of 36.36%. The firm increased its portfolio allocation in VALN by 154.25% over the last quarter.

In brief:
Moderna pauses its own Lyme disease program
Market potential for VLA15 exceeds USD 2 billion
Share considered technically heavily oversold

Valneva to Further Consolidate its Operations in France


November 26, 2025

French operations to be concentrated at its Lyon site
Final consolidation of R&D in Vienna
https://valneva.com/press-release/valneva-to-further-consolidate-its-operations-in-france/

Valneva Shares Rise on Positive Data from Lyme Disease Vaccine Study
https://www.wsj.com/health/pharma/valneva-shares-rise-on-positive-data-from-lyme-disease-vaccine-study-eb030e4d?siteid=yhoof2

!
November 26, 2025

Antibody levels remained well above baseline across all six serotypes and age groups sixth month after third yearly booster dose
No safety concerns observed in any age group by an independent Data Monitoring Committee (DMC)
Results confirm benefits of a yearly vaccination prior to each Lyme season

https://valneva.com/press-release/valneva-announces-positive-final-phase-2-results-for-lyme-disease-vaccine-candidate/

Valneva Reports Nine-Month 2025 Financial Results and Provides Corporate Updates
https://valneva.com/press-release/valneva-reports-nine-month-2025-financial-results-and-provides-corporate-updates/


November 20, 2025

Total revenues of €127.0 million compared to €116.6 million in the first nine months of 2024
Cash and cash equivalents of €143.5 million at end of September 2025
Financial flexibility enhanced with successful debt refinancing in October 2025 [1]
Lyme disease Phase 3 study VALOR on track
Updated 2025 financial outlook confirmed

sold some ABB, for https://investorshub.advfn.com/Beyond-Meat-Inc-BYND-36824
N for valNeva, do not confuse with BYD (chinese cars) without the "N" ,)

Highlights of the new facility include:

• Lowered cost of capital: Improved financial terms, including more favorable fixed
interest rate and lower prepayment and exit fees compared to previous debt facility

• Improved structure and flexibility: Converted from an amortizing structure to a more
capital efficient bullet maturity after five years, with no financial covenants

• Access to non-dilutive growth capital: Additional tranche(s) may be drawn for
purposes of future value creation through business development

Valneva Strengthens Financial Position by Refinancing Debt with Pharmakon Advisors and Provides Business Updates

https://valneva.com/press-release/valneva-strengthens-financial-position-by-refinancing-debt-with-pharmakon-advisors-and-provides-business-updates/

https://www-n--tv-de.translate.goog/wissen/Hunderte-Faelle-von-Infektionen-mit-Chikungunya-Virus-article26073194.html?_x_tr_sl=auto&_x_tr_tl=en&_x_tr_hl=de&_x_tr_pto=wapp

Valneva Reports 95% Seroresponse Four Years After Single Shot of Chikungunya Vaccine IXCHIQ®


Dear all,

Please find below a link to Valneva’s press release announcing positive antibody persistence data four years after vaccination with a single dose of its chikungunya vaccine IXCHIQ®. The results are in line with Valneva’s expectations for this vaccine, confirming a strong and long-lasting antibody persistence across all age groups investigated. The four-year persistence data are in line with previous persistence data, further highlighting a key advantage of the vaccine.

https://valneva.com/press-release/valneva-reports-95-seroresponse-four-years-after-single-shot-of-chikungunya-vaccine-ixchiq/

https://www1-wdr-de.translate.goog/nachrichten/rheinland/tigermuecke-rhein-sieg-kreis-100.html?_x_tr_sl=auto&_x_tr_tl=en&_x_tr_hl=en&_x_tr_pto=wapp

here we go


September 3, 2025

Strong immune response after third yearly booster dose in children and adults
Significant anamnestic antibody response across all six serotypes
No safety concerns observed in any age group by independent Data Monitoring Committee (DMC), consistent with previous booster results.

https://valneva.com/press-release/valneva-reports-further-positive-phase-2-safety-and-immunogenicity-results-for-lyme-disease-vaccine-candidate/

Authorized in Canada - Aged 12 and Older
Valneva’s Chikungunya Vaccine IXCHIQ Now Authorized in Canada for Individuals Aged 12 and Older
August 18, 2025

And now FDA? so what ... Let's see how things might turn out in China ,)

Very contradictory, makes very little sense, and is currently not transparent at all.
It doesn't matter for sales at the moment anyway.

" Sales of IXCHIQ ®
contributed €7.5 million to the Company’s €91 million total product sales in the first half of 2025, a
significant portion of which was the result of one-time delivery of vaccine doses to combat the chikungunya outbreak in La Reunion."

H.C. Wainwright starts with “buy” – target price of USD 18 causes a stir. Biotech stock Valneva is in the spotlight following a new valuation by H.C. Wainwright. Analyst Brandon Folkes initiated coverage of Valneva stock on August 19, 2025,
assigning it a clear “buy” rating.

ref. https://valneva.com/press-release/valnevas-chikungunya-vaccine-ixchiq-now-authorized-in-canada-for-individuals-aged-12-and-older/

Valneva has received expanded approval from Health Canada for its Chikungunya vaccine IXCHIQ, which can now be used for individuals aged 12 years and older.

"We also substantially reduced our spending and successfully
leveraged our ATM program to welcome two new leading healthcare investors among our main
shareholders, strengthening our financial position ahead of this important clinical catalyst.”

Key R&D, Regulatory, and Commercial Updates
• Finalized new $32.8 million IXIARO ® supply contract with the U.S. Department of Defense (DoD)
in January 2025 3
• Signed exclusive agreement with CSL Seqirus to market and distribute Valneva’s three
proprietary vaccines in Germany 4
• VALOR Lyme disease study on track; Pfizer confirmed all vaccinations have been completed 5
• Responded to French government’s call for vaccine supply of IXCHIQ ® to combat chikungunya
outbreak in La Réunion 6
• Announced European Medicines Agency (EMA) and Food and Drug Administration (FDA)’s
decisions to lift temporary restrictions on use of IXCHIQ ® in elderly following their thorough
review of the vaccine on reported serious adverse events (SAE’s) in that age group
• Secured additional marketing authorizations for IXCHIQ ® in the United Kingdom (UK) and Brazil 7 ,
marking the world’s first approval of a chikungunya vaccine in an endemic country 8
• Received label extension for IXCHIQ ® in Europe for individuals 12 years of age and older 9 and
submitted additional adolescent label extension applications in other countries"

Valneva Reports Half Year 2025 Financial Results and Provides Corporate Updates: 2025 financial outlook confirmed
Total revenues of €97.6 million compared to €70.8 million in the first half of 2024
Cash and cash equivalents of €161.3 million at end of June 2025
Further clinical and regulatory progress
https://valneva.com/press-release/valneva-reports-half-year-2025-financial-results-and-provides-corporate-updates/

"rmna stop": https://www.bbc.com/news/articles/c74dzdddvmjo

It should be noted that Valneva still has a unique non-mRNA treatment for COVID-19.
https://www.theguardian.com/world/2025/aug/05/us-covid-cases-rising

FDA hold finally lifted !!!
Valneva Announces Removal of FDA-Recommended Pause on Use of Chikungunya
https://valneva.com/press-release/valneva-announces-lifting-of-fdas-temporary-pause-on-use-of-chikungunya-vaccine-ixchiq-in-elderly-with-updates-to-the-prescribing-information/

(FR)... from the start of the outbreak in August 2024 through 4 May 2025, over 47 500 confirmed cases of chikungunya and more than 170 000 consultations for suspected chikungunya have been reported on the island. The surge in cases was observed from early 2025 with weekly case counts increasing from 30 at the end of 2024 to 4000 during the week of 10-16 March 2025 (epidemiological week 11), indicating more than a 100-fold increase.
https://www.who.int/emergencies/disease-outbreak-news/item/2025-DON567

Chikungunya Virus Is Spreading In China
According to the South China Morning Post, the city of Foshan alone has now recorded over 5,000 cases and has upgraded its emergency response to a level III – China’s public health system has four response tiers, with level I being the most serious emergency.
IXCHIQ
https://www.iflscience.com/chikungunya-virus-is-spreading-in-china-as-cdc-considers-travel-advisory-heres-what-to-know-80248

Hong Kong has confirmed its first imported case of chikungunya fever since 2019
https://www.scmp.com/news/hong-kong/health-environment/article/3320556/how-can-you-protect-yourself-if-hong-kong-has-chikungunya-fever-outbreak

Italy reports 32 cases, including 2 deaths, from West Nile virus amid spread of mosquito-borne illness
https://www.euronews.com/health/2025/07/24/italy-reports-32-cases-including-2-deaths-from-west-nile-virus-amid-spread-of-mosquito-bor

First Berlin Equity Research hat ein Research Update zu Valneva SE (ISIN: FR0004056851) veröffentlicht. Analyst Simon Scholes bestätigt seine BUY-Empfehlung und bestätigt sein Kursziel von EUR 8,10.
https://www.finanznachrichten.de/nachrichten-2025-07/66013997-original-research-valneva-se-von-first-berlin-equity-research-gmbh-buy-023.htm

= price target 8,10 EURO, so x2 = 18.84 $ via "VALN SE"

WHO/World Health Organization raises concern about spread of mosquito-borne Chikungunya virus

GENEVA, July 22 (Reuters) - The World Health Organization issued an urgent call for action on Tuesday to prevent a repeat of an epidemic of the mosquito-borne chikungunya virus that swept the globe two decades ago, as new outbreaks linked to the Indian Ocean region spread to Europe and other continents.
An estimated 5.6 billion people live in areas across 119 countries at risk from the virus, which can cause high fever, joint pain and long-term disability, Diana Rojas Alvarez, a medical officer at the WHO, told reporters in Geneva.

https://www.reuters.com/business/healthcare-pharmaceuticals/world-health-organization-raises-concern-about-spread-mosquito-borne-chikungunya-2025-07-22/

Valneva Announces Lifting of European Medicines Agency’s Temporary Restriction on Use of Chikungunya Vaccine IXCHIQ
https://valneva.com/press-release/valneva-announces-lifting-of-european-medicines-agencys-temporary-restriction-on-use-of-chikungunya-vaccine-ixchiq-in-elderly/

Exclusive Vaccine Marketing and Distribution Agreement for Germany with CSL Seqirus
https://valneva.com/press-release/valneva-announces-exclusive-vaccine-marketing-and-distribution-agreement-for-germany-with-csl-seqirus/

VLA1553: IXCHIQ® was well tolerated by children aged one to eleven years regardless of the dose or previous chikungunya infection (CHIKV)

https://valneva.com/press-release/valneva-reports-positive-six-month-antibody-persistence-and-safety-phase-2-results-in-children-for-its-single-shot-chikungunya-vaccine-ixchiq/

$VALN 🚨BREAKING: FDA makes the worst and most incomprehensible joke of all times.

The FDA is apparently pausing the use of Ixchiq - a vaccine no one has heard of and that has only seen 80,000 doses distributed. After a whopping 17 adverse events and 2 deaths the FDA and CDC are… https://t.co/aSpIZMOW3k pic.twitter.com/XEvpnJXMAr— Tom Renz (@RenzTom) May 10, 2025

On May 8, 2025, Valneva SE (VALN, Financial) received a revised price target from Guggenheim analyst Vamil Divan. The price target was lowered to $14.00 from the previous target of $15.00, marking a 6.67% decrease. Despite the adjustment in the price target, the analyst has maintained a 'Buy' rating on the stock.
https://www.gurufocus.com/news/2844423/valneva-valn-analyst-price-target-adjustment-by-guggenheim-valn-stock-news

Valneva Provides Update Following European Medicines Agency Announcement on Use of IXCHIQ® in Elderly
https://valneva.com/press-release/valneva-provides-update-following-european-medicines-agency-announcement-on-use-of-ixchiqin-elderly/

Valneva Reports First Quarter 2025 Financial Results and Provides Corporate Updates
https://valneva.com/press-release/valneva-reports-first-quarter-2025-financial-results-and-provides-corporate-updates/

May 7, 2025

Total revenues of €49.2 million compared to €32.8 million in the first quarter of 2024
Cash and cash equivalents of €153.0 million at end of March 2025
Further clinical and regulatory progress
2025 financial outlook confirmed

The results of a study conducted in the United States of 4,000 volunteers aged 18 to 65 and published in the scientific journal The Lancet were presented for approval.

The clinical trial showed that 98.9% of the participants produced neutralizing antibodies — which prevented the virus from entering cells — maintaining good levels for six months.

The chikungunya vaccine has also been approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency of the European Union.

“The expectation is that, once approved and with established production capacity, the vaccine will be incorporated into the national vaccination schedule, strengthening the fight against the disease in Brazil.”
Response sent by the Ministry of Health to SciDev.Net

Chikungunya is an arbovirus, given to diseases caused by arthropod-borne viruses such as mosquitoes and ticks. It is transmitted by the bite of the mosquito Aedes aegypti, the same vector of dengue and Zika.
(translated https://blogdopedlowski.com/2025/04/24/brasil-anuncia-vacina-contra-chikungunya/)

Ty I see it's 1.57 with analyst rating of $16
Will keep eye on it.
Ty

bought some AC Immune SA CH0329023102
3.200 USD ,)
one of the shares will hopefully be something "big" ,-) not sure ...
all takes too long

Valneva Receives First Marketing Authorization for IXCHIQ® in a Chikungunya Endemic Country
https://valneva.com/press-release/valneva-receives-first-marketing-authorization-for-ixchiq-in-a-chikungunya-endemic-country/

Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2
https://valneva.com/press-release/valneva-and-limmatech-announce-first-vaccination-in-phase-2-infant-study-of-tetravalent-shigella-vaccine-candidate-s4v2/

Thought you were only into tech stock good to see your into others.
What's your take with that tech stock, you posted
You like it or just think it's worth a buy
Pm me if you can
Ty

Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in EU for Adolescents Aged 12 and Above
https://valneva.com/press-release/valnevas-chikungunya-vaccine-ixchiq-now-authorized-in-eu-for-adolescents-aged-12-and-above/

Valneva Submits Adolescent Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to UK MHRA

https://valneva.com/press-release/valneva-submits-adolescent-label-extension-application-for-its-chikungunya-vaccine-ixchiq-to-uk-mhra/

Chikungunya Outbreak in La Réunion: Valneva Responds to French Government’s Call for Vaccine Supply
https://valneva.com/press-release/valneva-responds-to-french-governments-call-for-vaccine-supply-of-ixchiq-against-chikungunya-outbreak-in-la-reunion/


March 24, 2025

Saint Herblain (France), March 24, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it is responding to the chikungunya outbreak that is rapidly intensifying in France’s Island of La Réunion with its vaccine IXCHIQ®. In agreement and with support from the local public health agency, the Agence Régionale de Santé La Réunion, Valneva will provide 40,000 doses starting early April, with an option to provide more, through distribution agreements with the Island’s wholesalers. This supply of doses, paid for by the French authorities, is in line with the recommendation of France’s national public health agency, the Haute Autorité de Santé (HAS), to prioritize for vaccination adults aged 65 and over, with co-morbidities. IXCHIQ® remains available for purchase in France (mainland and overseas).

Chikungunya cases have spiked substantially in La Réunion since early 2025, with 8,600 cases recorded and almost 3,000 new cases during the week of March 3 to 9, 2025[1]. Similar to the 2005-2006 chikungunya outbreak, there is a risk of transmission to mainland France and other French overseas territories. Local authorities of La Réunion have published a Level 4 emergency crisis management plan to contain the outbreak, while the Centers for Disease Control and Prevention (CDC) agency of the United States (U.S.) also issued a travel alert as millions of international travelers visit France’s southern resorts and La Réunion Island annually.

Juan Carlos Jaramillo, M.D., Chief Medical Officer of Valneva, “Chikungunya outbreaks spread rapidly, so it is crucial to vaccinate as many people as possible to help contain the virus. We have the capacity to supply more doses and will continue working closely with Agence Régionale de Santé La Réunion to manage this outbreak locally and prevent its spread to other regions through international travel.”

IXCHIQ® is the world’s first licensed chikungunya vaccine available to address this significant unmet medical need. It is approved in the United States[2], Europe[3], Canada[4] and the United Kingdom[5] for the prevention of disease caused by the chikungunya virus in individuals 18 years of age and older. The European Medicines Agency (EMA) recently adopted a positive opinion recommending authorization of a label extension for IXCHIQ® to individuals 12 years of age and older[6].

On March 5, 2025, the Haute Autorité de Santé recommended to prioritize for vaccination adults aged 65 and over, especially those with comorbidities, followed by adults aged 18 and over with comorbidities, and vector control workers[7].

Valneva is focused on expanding the vaccine’s label and access. In the third quarter of 2024, the Company expanded its partnership with the Coalition for Epidemic Preparedness (CEPI)[8], with support from the EU Horizon Europe program, through a $41.3 million grant to advance broader access to the vaccine in Low- and Middle-Income Countries (LMICs), post-marketing studies and research to support potential label extensions in children, adolescents and pregnant women.

Within the framework of this partnership, Valneva recently announced the signing of an exclusive license agreement with the Serum Institute of India (SII)[9], the world’s largest manufacturer of vaccines by number of doses, enabling the supply of the vaccine in Asia, with a commitment to priority supply of the chikungunya vaccine at an affordable price to public health markets in LMICs.

This new agreement complements the license agreement Valneva signed in 2021 with Instituto Butantan in Brazil for the development, manufacturing and marketing of a local chikungunya vaccine at an affordable price for distribution in Latin American countries and selected LMICs affected by the disease.

Valneva Receives EMA’s Positive CHMP Opinion for Adolescent Label Extension for Chikungunya Vaccine IXCHIQ®
https://valneva.com/press-release/valneva-receives-emas-positive-chmp-opinion-for-adolescent-label-extension-for-chikungunya-vaccine-ixchiq/

Valneva Reports Preliminary Unaudited 2024 Revenue and Cash and Provides 2025 Outlook
https://valneva.com/press-release/valneva-reports-preliminary-unaudited-2024-revenue-and-cash-and-provides-2025-outlook/